Abstract
Background Delayed cerebral ischemia (DCI) is a significant complication of aneurysmal subarachnoid hemorrhage (aSAH). This study profiled immune responses after aSAH and evaluated their association with DCI onset.
Methods Twelve aSAH patients were enrolled. Leukocyte populations and cytokine levels were analyzed in cerebrospinal fluid (CSF) and peripheral blood (PB) on days 3, 5, 7, 10, and 14 post-aSAH. Peripheral blood mononuclear cells (PBMCs) were collected and their cytokine production quantified following stimulation.
Results Mixed-effects models revealed distinct immune cell dynamics in CSF compared to blood. Natural killer T cell frequency increased over time in CSF only, while monocyte/macrophage numbers increased in both CSF and PBMCs. CD4+ HLA II+ T cells increased in circulation. Unstimulated PBMCs showed increased IL-1β, IL-6, and TNFα production, peaking at 7 days post-aSAH, coinciding with typical DCI onset. Ex vivo stimulation of PBMCs showed that only IL-6 significantly changed over time. In CSF, cytokines peaked 5 days post-injury, preceding immune cell profile alterations.
Conclusions Our findings reveal a time-dependent immune response following aSAH, with distinct within-patient patterns in CSF and PB. The early CSF cytokine peak preceding immune cell changes suggests a potential mechanistic link and identifies the cytokine response as a promising therapeutic target. This cytokine surge may drive immune cell expansion and prime PBMCs for increased inflammatory activity, potentially contributing to DCI risk. Future studies should explore the importance and sources of specific cytokines in driving immune activation. These insights may inform the development of targeted immunomodulatory strategies for preventing or managing DCI in aSAH patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Our sincere thanks go out to all the research participants and their families. Some illustrations were created using BioRender.com. The research was supported by the University of Kentucky Neuroscience Research Priority Area. As well as National Institutes of Health grants: T32AG057461 (JL), R01NS103785 (ADB), R56AG069685 (BSN), R56AG074613 (AMS), and AHA 19EIA34760279 (AMS). The project described was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were collected from study participants with aSAH after approval by the University of Kentucky Institutional Review Board (IRB# 65452) and in accordance with the Declaration of Helsinki. All subjects and/or their authorized representatives signed written informed consent in accordance with Federal-wide Assurance on file with the Department of Health and Human Services (USA). All experiments were performed in accordance with relevant guidelines and regulations from 2020-2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Nonstandard Abbreviations and Acronyms
- SAH
- Subarachnoid hemorrhage
- aSAH
- Aneurysmal Subarachnoid Hemorrhage
- CSF
- cerebrospinal fluid
- DCI
- Delayed cerebral ischemia
- PB
- peripheral blood
- PBMCs
- Peripheral blood mononuclear cells
- RBC
- Red blood cell
- EVD
- external ventricular drain
- HH score/ H&H/ HH
- Hunt and Hess score
- Fisher
- Fisher grading scale for subarachnoid Hemorrhage
- WFNS
- The World Federation of Neurological Surgeons grading scale for subarachnoid hemorrhage
- Aneurysm Loc
- Aneurysm Location
- Ant.
- Anterior
- Post.
- Posterior
- Vaso
- Vasospasm presence
- FACS
- fluorescence-activated cell sorting
- UMAP
- Uniform manifold approximation and projection
- LPS
- Lipopolysaccharides
- BBB
- blood–brain barrier
- APCs
- antigen-presenting cells
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.